{"transactions":[{"id":691994,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25059,"kind":"organization","name":"venBio Global Strategic Fund IV, L.P.","position":1,"cik":"0001862109","reported_name":"venBio Global Strategic Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-08-10T20:12:09.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":6179219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund IV, L.P. (\"Fund IV\"). venBio Global Strategic GP IV, LLC (\"General Partner IV\") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the \"rule of three,\" each disclaims beneficial ownership over the securities held directly by Fund IV."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":665147},"source":{"system":"sec-edgar","filing":"0000905148-26-003548","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1862109/000090514826003548/form4.xml","form_type":"4"}},{"id":691993,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25059,"kind":"organization","name":"venBio Global Strategic Fund IV, L.P.","position":1,"cik":"0001862109","reported_name":"venBio Global Strategic Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T20:12:09.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":7636362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund IV, L.P. (\"Fund IV\"). venBio Global Strategic GP IV, LLC (\"General Partner IV\") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the \"rule of three,\" each disclaims beneficial ownership over the securities held directly by Fund IV."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":821998},"source":{"system":"sec-edgar","filing":"0000905148-26-003548","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1862109/000090514826003548/form4.xml","form_type":"4"}},{"id":691992,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25059,"kind":"organization","name":"venBio Global Strategic Fund IV, L.P.","position":1,"cik":"0001862109","reported_name":"venBio Global Strategic Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-10T20:12:09.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":21477273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund IV, L.P. (\"Fund IV\"). venBio Global Strategic GP IV, LLC (\"General Partner IV\") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the \"rule of three,\" each disclaims beneficial ownership over the securities held directly by Fund IV."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2311870},"source":{"system":"sec-edgar","filing":"0000905148-26-003548","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1862109/000090514826003548/form4.xml","form_type":"4"}},{"id":691991,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25059,"kind":"organization","name":"venBio Global Strategic Fund IV, L.P.","position":1,"cik":"0001862109","reported_name":"venBio Global Strategic Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T20:12:09.000Z","date":"2026-08-06","kind":"purchase","planned":false,"acquired":true,"shares":382352,"price":17,"value":6499984.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund IV, L.P. (\"Fund IV\"). venBio Global Strategic GP IV, LLC (\"General Partner IV\") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the \"rule of three,\" each disclaims beneficial ownership over the securities held directly by Fund IV."}],"balance_after":4181367,"source":{"system":"sec-edgar","filing":"0000905148-26-003548","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1862109/000090514826003548/form4.xml","form_type":"4"}},{"id":691990,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25059,"kind":"organization","name":"venBio Global Strategic Fund IV, L.P.","position":1,"cik":"0001862109","reported_name":"venBio Global Strategic Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T20:12:09.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":665147,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund IV, L.P. (\"Fund IV\"). venBio Global Strategic GP IV, LLC (\"General Partner IV\") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the \"rule of three,\" each disclaims beneficial ownership over the securities held directly by Fund IV."}],"balance_after":3799015,"source":{"system":"sec-edgar","filing":"0000905148-26-003548","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862109/000090514826003548/form4.xml","form_type":"4"}},{"id":691989,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25059,"kind":"organization","name":"venBio Global Strategic Fund IV, L.P.","position":1,"cik":"0001862109","reported_name":"venBio Global Strategic Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T20:12:09.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":821998,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund IV, L.P. (\"Fund IV\"). venBio Global Strategic GP IV, LLC (\"General Partner IV\") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the \"rule of three,\" each disclaims beneficial ownership over the securities held directly by Fund IV."}],"balance_after":3133868,"source":{"system":"sec-edgar","filing":"0000905148-26-003548","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862109/000090514826003548/form4.xml","form_type":"4"}},{"id":691988,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25059,"kind":"organization","name":"venBio Global Strategic Fund IV, L.P.","position":1,"cik":"0001862109","reported_name":"venBio Global Strategic Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T20:12:09.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":2311870,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the completion of the Issuer's initial public offering of its common stock (\"Common Stock\"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund IV, L.P. (\"Fund IV\"). venBio Global Strategic GP IV, LLC (\"General Partner IV\") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the \"rule of three,\" each disclaims beneficial ownership over the securities held directly by Fund IV."}],"balance_after":2311870,"source":{"system":"sec-edgar","filing":"0000905148-26-003548","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862109/000090514826003548/form4.xml","form_type":"4"}}]}